JATE JOURNAL APPLIED TISSUE ENGINEERING 2025, Vol11, No1

DOI:10.22034/JATE.2025.150

Genetically Engineered Cell Therapies, The Next Frontier in Regenerative Medicine

Melina Rajabi [1*]

[1)]Islamic Azad University Central Tehran Branch, Tehran, Iran.

* Corresponding author: melinarajabi780@yahoo.com .

Original Article Received: 20 May. 2025, Revised: 30 May 2025. Accepted: 2 June . 2025, ePublished: 7 June . 2025

Abstract

Introduction: Genetically engineered cell therapies (GECTs) represent a significant milestone in regenerative medicine that entails the application of living cells in conjunction with genetic modification to treat or prevent an extensive range of disease at their etiological axis. Cell and gene therapies are included in this category, and these have been of particular interest for the management of complex and otherwise refractory diseases such as cancer and inherited genetic disorders. One of the greatest achievements in the field was the 2017 FDA's approval of Kymriah, a CAR-T cell therapy for pediatric leukemia, that ushered the doors to a new age of personalized medicine. Development of GECTs has progressed since then with the emergence of gene-editing technologies such as CRISPR, which allow more precise and effective interventions. While therapeutic applicability is enormous, emergence of GECTs also presents important challenges. Areas of greatest contention involve ethical concerns about informed consent, long-term safety, and the possibility of unanticipated genetic consequences. Further, the cost of such therapy's limits availability to many, raising essential questions about healthcare equity and best methods of public versus private funding to distribute these services widely.Regulatory bodies such as the U.S. Food and Drug Administration are also changing their infrastructure to better accommodate these new treatments, attempting to balance safety with innovation. With all involved in the healthcare environment collaborating to address these issues, the science is moving very quickly. Collectively, GECTs hold game-changing promise to redefine disease treatment and improve patient care, at the forefront of medicine's future. Additional innovation and equitable use will be essential to realizing their full promise.

Keywords: Genetically engineered cell therapies, CAR-T cells, gene editing

Introduction

Historical Background

The evolution of genetically engineered cell therapies (GECTs) stems from pioneering research in the 1980s and 1990s, particularly the work conducted in Dr. Carl June's laboratory at the University of Pennsylvania (UPenn). These early studies laid the foundation for chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable success, particularly in hematologic malignancies like leukemia. The promising outcomes from early-phase clinical trials drew the attention of pharmaceutical companies. In 2012, a pivotal collaboration emerged between Novart and UPenn to commercialize CAR-T technology.

Novartis initially established a dedicated cell and gene therapy division, but by 2016, the unit was dissolved, with CAR-T development integrated into the broader oncology division. Although Novartis maintained its commitment to CTL019 (later branded as Kymriah), this restructuring raised questions about the sustainability of corporate investment in this emerging therapeutic area(1).

In parallel, regenerative medicine was advancing, especially through stem cell-based therapies aimed at tissue repair and regeneration. The focus increasingly shifted to autologous stem cell applications cells derived from the patient—to minimize immune rejection and bypass ethical concerns associated with embryonic or animal-derived sources(2).

As genetic engineering technologies such as CRISPR-Cas9 matured, the scope of these therapies broadened. Integration of gene editing with cell therapy opened new horizons for treating inherited disorders by correcting genetic mutations at the source. The intersection of cell therapy, gene therapy, and regenerative medicine now offers a comprehensive platform for the treatment of complex diseases(3,4).

However, this rapid innovation brings ethical and regulatory challenges. Issues such as informed consent, genetic data privacy, and equity in access especially given the high costs—are central to the responsible development of these therapies. The historical trajectory of GECTs thus reflects a dynamic interplay between scientific discovery, commercial strategies, regulatory frameworks, and ethical accountability(5).

Overview of Cell and Gene Therapies (GECTs)

GECTs represent a class of advanced therapeutic modalities that use living cells or genetic material to address the root causes of diseases, rather than merely alleviating symptoms. The two primary branches are:

1. Cell Therapy Mechanisms

Cell therapy involves the administration of live, functional cells into a patient to replace or repair damaged tissues. These cells may be autologous (from the same individual) or allogeneic (from a donor), and often undergo manipulation in a laboratory before reinfusion. A key example is CAR-T cell therapy, where a patient's T lymphocytes are genetically modified to express chimeric antigen receptors capable of recognizing and killing cancer cells(6).

2. Gene Therapy Mechanisms

Gene therapy involves the modification of genetic material within cells to correct disease-causing mutations or enhance cellular function. This is typically achieved via:

Viral vectors (e.g., lentivirus, AAV) to deliver therapeutic genes, Gene-editing tools like and RISPR-Cas9, which enable precise editing of specific DNA sequences(7).

CRISPR's accuracy, scalability, and cost-effectiveness have positioned it as a powerful tool in the treatment of a broad spectrum of diseases, including genetic disorders, cancers, and autoimmune conditions(8).

Combined Therapeutic Approaches

In many clinical scenarios, hybrid strategies that combine cell and gene therapy are employed. For instance, gene editing may be used to enhance immune cell function before applying them in cell-based immunotherapies for cancer. Similarly, synthetic biology techniques are now enabling the engineering of cells with novel or augmented capabilities, enhancing their therapeutic impact(3,8).

Challenges and Considerations

Despite the substantial promise of GECTs, several critical challenges remain: Medical Risks: Potential side effects include cytokine release syndrome (CRS), neurotoxicity, and increased risk of infections due to immune modulation(9). Long-term Safety: The integration of foreign genetic material raises concerns about insertional mutagenesis, which may lead to unintended oncogenesis. Ethical Concerns: These include informed consent for highly technical procedures, privacy risks

associated with genetic data, and accessibility inequalities due to the high cost of these therapies(2).

Applications of Genetically engineered cell therapies

Genetically Engineered Cell Therapy (GECT) is an emerging modality in regenerative medicine that integrates principles of gene therapy and cellular therapy. It involves the genetic modification of patient-derived cells to correct inherited genetic defects or enhance cellular resistance against various diseases, including cancers and genetic disorders(10).

Applications in Cancer Immunotherapy

One of the most prominent applications of GECT is in cancer treatment, particularly through cellular immunotherapy strategies such as CAR T-cell therapy. In this approach, a patient's T cells are genetically modified to express chimeric antigen receptors (CARs) that enable them to recognize and destroy cancer cells more effectively(11).

CAR T-cell therapy has demonstrated remarkable clinical efficacy, especially in hematologic malignancies such as B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. For patients with otherwise limited treatment options, these therapies offer a powerful, targeted, and personalized solution(12).

Treatment of Genetic Disorders

Another transformative application of GECT is in the treatment of inherited genetic conditions. Notable examples include sickle cell anemia and hemophilia. By targeting the underlying genetic mutations, gene therapies offer long-term or even curative solutions, eliminating the need for frequent conventional treatments.

For instance, Casgevy, a CRISPR/Cas9-based therapy, edits the patient's hematopoietic stem cells to restore the production of fetal hemoglobin, significantly reducing the severity of sickle cell disease. Similarly, Hemgenix, approved for the treatment of hemophilia B, delivers a functional F9 gene to the liver cells, enabling production of the missing clotting factor IX(13,14).(15)

Advances in Combined Therapeutic Modalities Beyond standalone applications, GECT is being integrated with other therapeutic strategies to treat complex, multi-system disorders. Techniques such as ex vivo gene editing of immune or stem cells enhance their functionality before reinfusion into the patient(16,17).

These integrative approaches are paving the way for personalized medicine, where treatments are tailored to an individual's genetic profile. This not only improves therapeutic outcomes but also reduces adverse effects, representing a major step forward in patient-specific care(5).

GECT holds immense promise across a broad spectrum of diseases. From enabling immune cells to target cancer to correcting life-threatening genetic disorders, this technology is reshaping the future of medicine. Continued advances in gene editing tools and delivery systems will further expand its applications, offering hope to patients with previously untreatable conditions(2).(15)

Regulatory Initiatives and Support Programs

To support the advancement of GECT, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have implemented supportive programs, including the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) and the INTERACT meeting program. These initiatives aim to streamline clinical development by providing early-stage guidance and fostering transparent communication between sponsors and the regulatory staff.15-16 However, with the growing volume of regulatory submissions—especially for rare diseases—there is an increasing need for innovative approaches to ensure patient safety, data readiness, and efficiency in decision-making processes(6,18).

Regulatory and Ethical Considerations

Evolving Regulatory Frameworks

Genetically engineered cell therapies often fall into a

regulatory gray area, combining features of pharmaceuticals, biologics, and medical devices. As a result, approval pathways are often complex, and vary between regions. While the FDA and European Medicines Agency (EMA) have established processes, other regions (e.g., in Asia or Africa) may impose stricter or slower procedures.5 This lack of harmonization poses barriers to global commercialization. Ongoing international efforts are underway to align standards in areas such as manufacturing, quality control, and safety testing, to promote broader and faster access to GECT worldwide(19,20).

Ethical Implications

Ethical challenges surrounding GECT include: Informed consent: Many patients struggle to understand the complexities and risks of gene modification, Equitable access: The high cost of therapies limits availability, especially in lower-income settings and Long-term safety: Uncertainties regarding long-term outcomes and risks, such as immune reactions and off-target effects, necessitate continuous ethical oversight. Policymakers are encouraged to develop tiered pricing models, public-private partnerships, and transparent communication strategies to ensure fairness and patient autonomy(21).

Safety, Monitoring, and Informed Consent

Safety Surveillance

Post-marketing surveillance is critical to address potential adverse immune responses, insertional mutagenesis, or unforeseen complications from gene editing. Agencies such as the FDA and EMA must maintain adaptive monitoring systems that allow real-time safety updates and revisions of clinical guidelines based on emerging data(22).

Dynamic Informed Consent

Informed consent should not be viewed as a one-time event, but rather a continuous dialogue. As new safety and efficacy data become available, patients should have the opportunity to reassess their treatment options. This is especially crucial in germline editing, where the implications may extend across generations, demanding strict ethical boundaries and legal oversight(23).

Key Challenges and Limitations

Pre-Market Challenges

Ethical Design of Clinical Trials clinical trial designs for GECT—particularly for CAR-T cell therapies—must carefully address: Target population selection, Informed recruitment strategies, Management of adverse events and Ethical endpoint selection1

Access and Equity High treatment costs and a limited number of authorized centers restrict access. Lack of collaboration with patient advocacy groups may further isolate patient interests from the innovation pipeline (24).

Post-Market Challenges

Integration into Standard Care As GECT becomes more widespread, transitioning these therapies into front-line treatments requires systemic changes in health infrastructure, education of healthcare providers, and coordination among stakeholders to ensure safe and ethical deployment(25).

Manufacturing and Commercialization Barriers Bringing a GECT product to market can cost upwards of $1.9 billion. Common obstacles include: Bottlenecks in production scale-up, Supply chain instability, Shortage of skilled personnel and Quality control issues (26,27).

Regulatory Complexity and Global Variations Differences in regulatory requirements across jurisdictions (e.g., for trial design or manufacturing standards) lead to increased development costs and potential delays. In some cases, regulatory agencies participate in pricing discussions to improve affordability, but this must be carefully balanced with the incentive for innovation(28).

Long-Term Risk Management

Ongoing data collection is crucial for identifying long-term complications such as tumorigenesis due to insertional mutations, especially in therapies using viral vectors. Robust systems must be in place for tracking and responding to such events.

While genetically engineered cell therapies represent a revolutionary step in regenerative medicine, their successful development and integration into healthcare systems depend on proactive regulatory frameworks, ethical integrity, and global collaboration. Addressing the complexities of safety, access, and manufacturing will be essential to realizing the full potential of these transformative therapies(29).

Financial and Access Issues in GECT

Cost-Effectiveness and Affordability

Despite the transformative potential of cell and gene therapies (CGTs), high upfront costs pose a substantial barrier to their widespread adoption. While long-term health benefits such as disease remission or potential cure may justify the initial investment, the immediate financial burden on healthcare systems and patients remains significant, especially in low- and middle-income countries (LMICs) with underdeveloped healthcare infrastructure (30).

Innovative Pricing Models and Access Equity

To mitigate disparities in access, experts advocate for tiered pricing models, which adjust therapy costs according to a country's economic status. This model promotes global equity by making therapies more affordable in resource-limited settings. Additionally, public-private partnerships, government subsidies, and nonprofit engagement could help facilitate CGT development and distribution in underserved regions, aligning innovation with social responsibility(26).

Regulatory Innovations and Global Harmonization

The regulatory environment is evolving to support CGT innovation. Key recent developments include:

Rare Disease Innovation Hub: Established by the FDA to strengthen collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), this hub facilitates a unified approach to rare disease therapy regulation.

CoGenT Global Pilot Program: Aims to encourage international regulatory convergence by allowing foreign agencies to participate in joint reviews with the FDA. This collaboration enhances transparency, accelerates decision-making, and fosters trust among global stakeholders(31).

These initiatives highlight the importance of international coordination and early, ongoing engagement between developers and regulators in navigating the complex and evolving landscape of CGTs.

Advancements in Research and Development

The CGT research pipeline is rapidly expanding, with over 1,000 active clinical trials as of 2022 (32). However, early-stage companies face critical hurdles, including: Limited manufacturing capacity, High R&D costs and Need for rapid proof-of-concept data

To overcome these obstacles, researchers are investing in scalable manufacturing technologies, automated production systems, and adaptive clinical trial designs, particularly those tailored to rare diseases, which often require patient-specific engagement strategies(33).

The emphasis on patient-centric development—including real-world data collection, decentralized trials, and patient advisory boards—is essential to ensure both ethical integrity and clinical relevance.

References

1. 1.Imbach KJ, Patel A, Levine AD. Ethical Considerations in the Translation of CAR-T Cell Therapies. Cell Gene Ther Insights. 2018 May 14;4(4):295–307.
2. 2.Harris AR, Walker MJ, Gilbert F. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. BMC Med. 2022 Dec 27;20(1):499.
3. 3.Milone MC, Mansilla-Soto J, Pardi N, George LA, Byrne BJ, Herzog RW. Clinical advances in gene, cell, and RNA therapies. Molecular Therapy. 2025 May;
4. Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023 Jan 16;8(1):36.
5. 5.TAMURA R, TODA M. Historic Overview of Genetic Engineering Technologies for Human Gene Therapy. Neurol Med Chir (Tokyo). 2020;60(10):483–91.
6. 6.Silva AC. Cell Therapy. In 2024. p. 57–64.
7. 7.Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, et al. Gene therapy: Comprehensive overview and therapeutic applications. Life Sci. 2022 Apr;294:120375.
8. 8.Aiyegbusi OL, Macpherson K, Elston L, Myles S, Washington J, Sungum N, et al. Patient and public perspectives on cell and gene therapies: a systematic review. Nat Commun. 2020 Dec 8;11(1):6265.
9. 9.Gonçalves GAR, Paiva R de MA. Gene therapy: advances, challenges and perspectives. Einstein (São Paulo). 2017 Sep;15(3):369–75.
10. 10. Yong SB, Chung JY, Song Y, Kim YH. Recent challenges and advances in genetically-engineered cell therapy. J Pharm Investig. 2018 Mar 28;48(2):199–208.
11. 11. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May 18;94(S1).
12. 12. Elmarasi M, Elkonaissi I, Elsabagh AA, Elsayed E, Elsayed A, Elsayed B, et al. CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up. Int Immunopharmacol. 2024 Jun;135:112312.
13. 13. Morgan RA, Gray D, Lomova A, Kohn DB. Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell. 2017 Nov 2;21(5):574–90.
14. 14. Leonard A, Tisdale JF. Gene therapy for sickle cell disease. Hematology. 2023 Dec 8;2023(1):542–7.
15. 15. Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Gene and cell therapy of human genetic diseases: Recent advances and future directions. J Cell Mol Med. 2024 Sep 8;28(17).
16. Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent Advances in Combined Modality Therapy. Oncologist. 2010 Apr 1;15(4):372–81.
17. 17. Azevedo A, Farinha D, Geraldes C, Faneca H. Combining gene therapy with other therapeutic strategies and imaging agents for cancer theranostics. Int J Pharm. 2021 Sep;606:120905.
18. 18. Mendicino M, Fan Y, Griffin D, Gunter KC, Nichols K. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. 2019 Jul;21(7):699–724.
19. 19. Pimenta C, Bettiol V, Alencar-Silva T, Franco OL, Pogue R, Carvalho JL, et al. Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future. Clin Ther. 2021 May;43(5):e103–38.
20. 20. Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021 Jun;21:524–9.
21. 21. Ansah EO. Ethical Challenges and Controversies in the Practice and Advancement of Gene Therapy. Adv Cell Gene Ther. 2022 Aug 24;2022:1–5.
22. 22. Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev. 2021 Jun;21:524–9.
23. 23. Dankar FK, Gergely M, Malin B, Badji R, Dankar SK, Shuaib K. Dynamic-informed consent: A potential solution for ethical dilemmas in population sequencing initiatives. Comput Struct Biotechnol J. 2020;18:913–21.
24. 24. James Riddle. https://www.contractpharma.com/exclusives/gene-therapy-is-having-its-moment-can-the-clinical-research-ecosystem-seize-it/. 2024. Gene Therapy is Having its Moment: Can the Clinical Research Ecosystem Seize It?
25. 25. American Society of Gene & Cell Therapy. https://patienteducation.asgct.org/gene-therapy-101/cell-therapy-basics. Cell Therapy Basics.
26. 26.: Meghan Hosely. https://www.advarra.com/blog/regulatory-trends-in-cell-and-gene-therapies/. 2022. Regulatory Trends in Cell and Gene Therapies.
27. 27. Priyom Bose. https://www.news-medical.net/life-sciences/The-Latest-Advances-in-Cell-and-Gene-Therapy.aspx. 2025. The Latest Advances in Cell and Gene Therapy.
28. 28. Spichkova M, Schmidt HW, Nekvi MRI, Madhavji NH. Structuring diverse regulatory requirements for global product development. In: 2015 IEEE Eighth International Workshop on Requirements Engineering and Law (RELAW). IEEE; 2015. p. 57–60.
29. 29. Michelle Meyer et al. Data Risks and Costs. In: Planning for Long-Term Use of Biomedical Data: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2020.
30. 30. Zhang JX, Shugarman LR. Value-based payment and financing for cell and gene therapies: challenges and potential solutions. J Med Econ. 2024 Dec 31;27(1):678–81.
31. 1.Imbach KJ, Patel A, Levine AD. Ethical Considerations in the Translation of CAR-T Cell Therapies. Cell Gene Ther Insights. 2018 May 14;4(4):295–307.
32. 2.Harris AR, Walker MJ, Gilbert F. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. BMC Med. 2022 Dec 27;20(1):499.
33. 3.Milone MC, Mansilla-Soto J, Pardi N, George LA, Byrne BJ, Herzog RW. Clinical advances in gene, cell, and RNA therapies. Molecular Therapy. 2025 May;
34. 4.Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023 Jan 16;8(1):36.